• Ticker

DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$7.35 $0.03 (0.41%)

REAL-TIME: Last trade at

ACHILLION PHARMACEUTICALS, INC...

NASDAQ:ACHN

Achillion announces additional proof-of-concept data with ACH-2684 for HepC

Achillion Announces Additional Proof-of-Concept Data With ACH-2684 for the Treatment of Hepatitis C

Achillion Announces Executive Promotion

Achillion rises 7.4%

Achillion gaps up after ACH-3102 fast-tracked, resistance at $7.63, $8.09

ACH-3102 Receives Fast Track Designation From the FDA for the Treatment of Chronic Hepatitis C

Achillion shares at good entry point, says RW Baird

Achillion reports Q1 EPS (13c), consensus (15c)

Achillion Pharmaceuticals, Inc. (ACHN) Tops Q1 EPS by 2c

Achillion Reports First Quarter 2012 Financial Results

Achillion Pharmaceuticals (ACHN) Upgraded To 'Neutral' By UBS, PT Trimmed

Achillion upgraded to Neutral from Sell at UBS

Pharmaceutical Companies Look to Biotech Industry to Combat Losses from Expiring Patents

Baird Maintains an 'Outperform' on Achillion Pharmaceuticals (ACHN); Reassuring Clarification on '1625

Achillion '1652 still looks highly effective, says RW Baird

Achillion falls 17.5%

Achillion falls 13.2%

Achillion gaps down, support now at $7.05

Achillion clarifies end of treatment data from Phase 2a trial of ACH-1625

Achillion Clarifies End of Treatment Data From Phase 2a Trial With ACH-1625 Based Regimen in Hepatitis C

Achillion falls 14.4%

Achillion valuation range lowered to $11-$13 from $14-$16 at Wells Fargo

Achillion removed from near-term focus list at Brean Murray

Achillion downgraded to Market Perform from Outperform at JMP Securities

Grading Hep C Stocks Exiting EASL Confab

Achillion announces 94 - 100% complete EVR from ACH-1625 trial

Achillion Announces 94 - 100% Complete EVR From Phase 2 Trial With ACH-1625 Based Regimen in Hepatitis C

Achillion Announces 94 - 100% Complete EVR From Phase 2 Trial With ACH-1625 Based Regimen in Hepatitis C

Baird Reiterates an 'Outperform' on Achillion Pharmaceuticals (ACHN); Buy on Weakness

Achillion weakness a buying opportunity, says JMP Securities

Achillion falls 15.7%

Achillion weakness unjustified, says Wells Fargo

Achillion shares defended at Brean Murray

Achillion weakness an overreaction, says Wells Fargo

Achillion falls 22.1%

UBS Upgrades Achillion Pharmaceuticals (ACHN) to Neutral

Achillion downgraded at UBS

Achillion shares gap down, support is at $7.54

Achillion downgraded to Sell from Neutral at UBS

Achillion falls 7.8%

See More Articles...